- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2015 (2015), Article ID 895976, 12 pages
Icariin Intervenes in Cardiac Inflammaging through Upregulation of SIRT6 Enzyme Activity and Inhibition of the NF-Kappa B Pathway
1Center of Disease Prevention and Treatment, Shanghai Guanghua Hospital of Integrative Traditional Chinese and Western Medicine, Shanghai 200052, China
2Department of Geriatrics, Shanghai Institute of Geriatrics, Huadong Hospital, Fudan University, Shanghai 200040, China
3Department of Perinatal Medicine, Pregnancy Research Centre and University of Melbourne Department of Obstetrics and Gynaecology, Royal Women’s Hospital, Parkville, VIC 3052, Australia
4Medical College, China Three Gorges University, Yichang 443002, China
5Key Laboratory of Cellular and Molecular Biology, Huashan Hospital, Fudan University, Shanghai 200040, China
6Department of Diseases Prevention and Healthcare, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Received 19 June 2014; Revised 23 July 2014; Accepted 7 August 2014
Academic Editor: Javier González-Gallego
Copyright © 2015 Yang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The aim of the study was to investigate the effect of icariin (ICA) on cardiac aging through its effects on the SIRT6 enzyme and on the NF-κB pathway. Investigating the effect of ICA on the enzymatic activity of histone deacetylase SIRT6 revealed a concentration of 10−8 mol/L ICA had a maximum activating effect on histone deacetylase SIRT6 enzymatic activity. Western analysis showed that ICA upregulated SIRT6 protein expression and downregulated NF-κB (p65) protein expression in animal tissues and cell models. ICA upregulated the expression of SIRT6 and had an inhibitory effect on NF-κB inflammatory signaling pathways as shown by decreasing mRNA levels of the NF-κB downstream target genes TNF-α, ICAM-1, IL-2, and IL-6. Those effects were mediated directly or indirectly by SIRT6. We provided evidence that inflammaging may involve a novel link between the effects of ICA on SIRT6 (a regulator of aging) and NF-κB (a regulator of inflammation).
Icariin is an important, active component in Herba Epimedii. This well-known Chinese herbal medicine has proven efficacy in treating cardiovascular diseases and osteoporosis and in improving sexual and neurological function and is widely used to treat particular age-related diseases in oriental countries [1, 2]. Total flavone of Epimedium (TFE) is generally considered to be the active compound found in Herba Epimedii. Previous studies found that TFE prolongs the lifespan and has strong effects in 2BS cells , C. elegans , and Drosophila . In addition, urine and plasma metabonomic studies showed TFE treatment altered age-related changes in aging rats to levels consistent with younger rats [6, 7]. Icariin represents an important active component in TFE and exhibits similar life prolonging effects of TFE in C. elegans  and mice. A significant feature of the natural aging process is that body function decline is chronic and progressive; therefore the desired intervention drug must have a therapeutic effect as well as being safe, have nontoxic side effects, and be suitable for long-term use. ICA fulfills these requirements as an aging intervention drug and has been studied extensively over many years.
Worldwide, research on delaying aging has a major focus on the silent information regulation protease family of Sirtuins . Sirtuins belong to the Sir2 family of NAD(+)-dependent deacetylases and they regulate longevity in yeast, C. elegans, and Drosophila. In mammals, there are seven homologs of the yeast Sir2, Sirt1-7 [10, 11]. Current research on antiaging focuses mainly on SIRT1 and SIRT6 [12, 13]. There is strong experimental evidence to support that SIRT6, not SIRT1, is the enzyme responsible for prolonging the lifespan of higher organisms. SIRT6-deficient mice are small and at 2-3 weeks of age develop abnormalities that include profound lymphopenia, loss of subcutaneous fat, lordokyphosis, and severe metabolic defects. These mice eventually die after about 4 weeks. An important function of SIRT6 is to promote normal DNA repair, and SIRT6 loss leads to abnormalities in mice that have similarities with aging-associated degenerative processes . Moreover, other research suggests that SIRT6 maintains genomic stability, and SIRT6 regulates glucose and fat metabolism, thereby inhibiting the inflammatory response. In the near future, SIRT6 research is expected to lead to new therapies for neurodegenerative diseases, metabolic diseases, and premature aging [15, 16].
Researchers are increasingly linking aging and inflammation, and they are focusing their attention on the NF-kappa B (NF-κB) signaling pathway , which is a conserved signaling pathway that is active in the host immune response system. Not only does the NF-κB signaling pathway regulate inflammation, oxidative stress and genotoxic stress, but it is also involved in the self-regulation of homeostatic functions such as apoptosis, autophagy, and tissue atrophy. SIRT1, SIRT6, and FOXO genes are important genes that can inhibit inflammaging caused by the NF-κB signaling pathway . NF-κB is a stress-responsive transcription factor that induces expression of target genes involved in aging-related processes including cell senescence, apoptosis, and inflammation. NF-κB signaling is regulated by SIRT6, which is recruited to NF-κB target gene promoters by physical interaction with the NF-κB (P65) subunit RELA. SIRT6 deacetylates histone H3 lysine 9 on target gene promoters, thereby altering chromatin structure to facilitate NF-κB destabilization and signal termination .
Numerous studies suggest that ICA can inhibit the NF-κB signaling pathway and reduce the body’s inflammatory response. Given the evidence that ICA can delay aging and prolong average and maximum life expectancy, it is uncertain whether ICA acts on SIRT6 and the NF-κB signaling pathways. Thus, the aim of the study was to provide experimental evidence that ICA acts through SIRT6 and the NF-κB signaling pathway to prevent inflammaging.
2. Materials and Methods
Healthy male BALB/c mice that were specific pathogen-free (SPF) and 8~9 weeks of age were provided by Vital River Laboratory Animal Technology Co. Ltd. All procedures for handling animals were approved by the Animal Experimentation Committee of Laboratory Animal Center of Shanghai Public Health Clinical Center. 23 mice were fed to 12 months of age in single cage and then randomly divided into a normal control group (, fed by feed pellets) and an ICA-treated group (, fed by feed pellets contained in 0.02% ICA for 3 months when the mice were 21 months old). Three-month old mice were used as the young control group (), and when mice were 24 months of age they were used as the aged group (). Mice were fed ad libitum, and tissue specimens from the heart were taken for testing.
2.2. Chemicals and Reagents
ICA (98.5% pure and provided by Shanghai Second Military Medical University) was used for the preparation of mouse feed. Mouse feed was mixed with ICA powder, dried at 70~90°C, sterilized, and then prepared into feed pellets. The NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC), 1-methyl-3-isobutyl-xanthine (IBMX), dexamethasone, synthetic human insulin, and SIRT6 enzyme inhibitor nicotinamide were purchased from Sigma (USA). High glucose DMEM medium and fetal bovine serum were purchased from Gibco. Trizol was purchased from Invitrogen. Real-time PCR kits were purchased from TaKaRa (Japan). Rabbit anti-SIRT6 was purchased from Abcam (UK). Mouse-specific NF-κB (p65) antibody was from Cell Signal Technology (USA) and HRP-conjugated anti-rabbit secondary antibody was purchased from Beyotime (Shanghai, China).
2.3. Protocol for Murine Aortic Endothelial Cell (ECs) Culture
Three-month old murine aortic ECs were isolated and cultured by enzymatic dissociation as previously described [20, 21]. Briefly, the full length of the thoracic aorta was removed from mice under sterile conditions, rinsed 3 times with phosphate-buffered saline solution (PBS), and placed into a 100-mm culture dish (Corning, NY, USA) filled with serum-free Dulbecco modified Eagle medium (DMEM, Hyclone, Logan, UT) on ice. The vessel was gently cleaned of periadventitial fat and connective tissue. The thoracic aorta was opened and rinsed with serum-free DMEM, placed intimal side down on a sterile plate containing 0.2% collagenase type I (Sigma, St. Louis, MO), and incubated at 37°C for 30 min. Cells were gathered by gentle abrasion with a cell scraper (Costar, Pleasanton, CA) from the edges to the center of the specimen and then rinsed with 5 mL of DMEM plus serum to arrest the digestion process. The medium containing detached ECs was collected and the cell suspension was centrifuged at 2000 rpm for 10 minutes. The cell pellet was washed twice, suspended in DMEM supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 U/mL penicillin, 100 μg/mL streptomycin, and 75 μg/mL endothelial cell growth supplement (sigma, USA), and placed into a 60-mm culture dish (Corning, USA). The dish was then placed in a humidified incubator at 37°C with 5% CO2. Thereafter, the medium was changed every other day. Once the cells had formed a monolayer, the cells were subcultured. More than 95% of the cells were positive for von Willebrand factor antibody (sc-59810, Santa Cruz, USA) staining (data not shown).
2.4. Detection of Senescence-Associated β-Galactosidase (SA-β-Gal) In Vitro
Cell Grouping: Three-month old murine aortic ECs were divided into three groups: normal, TNF-α-treated, and TNF-α-treated with ICA intervention. In the TNF-α-treated group, exogenous TNF-α (10 ng/mL) was added into cell culture solution for 36 hours. Subsequently, TNF-α (10 ng/mL) was added again for 36 hours to the TNF-α-treated group. In the TNF-α-treated with ICA intervention group, exogenous TNF-α (10 ng/mL) and ICA (10−8 mol/L) were simultaneously added into cell culture solution for 36 hours, and then TNF-α (10 ng/mL) was added separately for 36 hours.
A senescence-associated β-galactosidase (SA-β-gal) staining kit (Beyotime, Shanghai) was used according to the manufacturer’s protocol. Briefly, cells were seeded at subconfluence in a 6-well plate and further incubated in serum-free medium for 24 hours. Cells were then treated according to the above groups. After 72 h, cells were washed twice with PBS; 1 mL X-gal dye was added into each well and then incubated at 37°C, 5% CO2 for 4 hours. The percentage of SA-β-gal-positive cells was determined by counting the number of blue cells under bright-field illumination and the total number of cells in the same field under phase contrast. At least 5 random fields were counted for each culture dish.
2.5. Administration Aortic Endothelial Cells (ECs) Experiments
Young murine aortic ECs were divided into seven groups: (1) young treated with PBS, (2) young treated with DMSO, (3) young + TNF-α, (4) young + TNF-α + ICA (10−8 mol/L), (5) young + TNF-α + ICA + PDTC, (6) young + TNF-α + ICA + Nicotinamide, and (7) young + TNF-α + ICA + PDTC + Nicotinamide. Groups 1 and 2 were controls treated with PBS and DMSO, respectively, for 12 hours. Groups 3–6 were all treated with exogenous TNF-α (10 ng/mL for 30 min to generate mild inflammation). Treatments with ICA, PDTC (final concentration of PDTC is 10 μM), and Nicotinamide (final concentration of Nicotinamide is 50 mM) were for 12 hours.
2.6. SIRT6 Enzyme Activity Test In Vitro
ICA (molecular weight 676.65) was dissolved in DMSO to prepare different working concentrations as follows: 10−4, 10−6, 10−8, 10−10, 10−12, 10−14, and 10−16 mol/L. The SIRT6 Direct Fluorescent Screening Assay Kit (Cayman Chemical Company, USA) was used to test the activation effect of ICA on SIRT6 enzymatic activity. The assay was carried out according to the manufacturers’ instructions. The assay wells comprised 100% initial enzyme activity wells (added SIRT6 enzyme and DMSO), background wells (added DMSO alone), and sample wells (added SIRT6 enzyme and different ICA concentrations). The plates were read within 30 min using a microplate reader (TECAN, USA) with an excitation wavelength of 350–360 nm and an emission wavelength of 450–460 nm. The background well values were subtracted from the 100% initial activity wells and from the sample wells. The following equation was used to calculate the percent activation. %Activation = [(initial activity − sample)/initial activity] × 100.
2.7. Western Blot Analysis
Murine heart tissue protein was extracted according to the manufacturer’s instructions. Protein concentrations were measured using a BCA Protein Assay (Rockford, IL). Equal amounts of protein were loaded onto 10%–15% SDS-PAGE gels, transferred to nitrocellulose (NC) membranes, and blocked with 5% nonfat milk in TBST buffer (0.121% Tris-HCl, 0.9% NaCl, and 0.1% Tween-20, PH7.5) for 1 hour. Membranes were incubated with a 1 : 1000 dilution of primary SIRT6 antibody or a 1 : 2000 dilution of NF-κB (p65) antibody. After washing, the blots were incubated with a 1 : 2000 dilution of horseradish peroxidase- (HRP-) labeled IgG secondary antibody for 1 hour. Signals on the blots were then developed using the enhanced chemiluminescence (ECL) system and analyzed by an Odyssey Imager (Li-COR Biosciences, USA). Densitometric analysis was performed with ImageJ software (National Institute of Health, Bethesda, MD, USA).
2.8. Reverse Transcription and Semiquantitative Real-Time Polymerase Chain Reaction Assay
Lysed murine aortic ECs were transferred into a tube containing Trizol, and total RNA was isolated according to the manufacturer’s protocol. Total RNA was used for cDNA synthesis and the RT-PCR was carried out according to the manufacturer’s instructions. The PCR was performed in a commercial real-time thermocycler (ABI Prism 7000, Applied Biosystems, Germany) using the following cycle parameters: a 94°C predenaturation for 3 min, followed by 35 cycles of 94°C for 40 seconds, 56°C for 50 seconds, and 72°C for 90 seconds, and an extension cycle of 70°C for 10 min. The target gene transcripts in each sample were normalized to the levels of human GAPDH (glyceraldehydes-3-phosphate dehydrogenase). The primers used were as follows: SIRT6 forward, 5′-AGGCCGTCTGGTCATTGTC-3′, reverse, 5′-GCACATCACCTCATCCACGTA-3′; TNF-α forward, 5′-GCACCACCATCAAGGACTCAAATG-3′, reverse, 5′-GACAGAGGCAACCTGACCACTC-3′; ICAM-1 forward, 5′-GGAGACGCAGAGGACCTTAACAG-3′, reverse, 5′-CGACGCCGCTCAGAAGAACC-3′; IL-2 forward, 5′-TCACCCTTGCTAATCACTCCTCAC-3′, reverse, 5′-TGCTGCTGCTGCTGCTGTG-3′; IL-6 forward, 5′-AACCGCTATGAAGTTCCTCTC-3′, reverse, 5′-TCCTCTGTGAAGTCTCCTCT-3′; GAPDH forward, 5′-GGCACAGTCAAGGCTGAGAATG-3′, reverse, 5′-ATGGTGGTGAAGACGCCAGTA-3′.
2.9. Immunocytochemistry of NF-κB (p65) Nuclear Translocation by Confocal Laser Scanning Microscopy
ECs were plated on glass coverslips and fixed in methanol and acetone (1 : 1) overnight at 4°C. After washing, samples were permeabilized for 15 min with buffer containing saponin (50 mm Tris, 200 mm NaCl, and 0.05% saponin, pH7.5) at room temperature. Cells were subsequently incubated with buffer (50 mm Tris, 200 mm NaCl, pH7.5) containing 3% goat serum for 30–60 min to block nonspecific binding. To identify cell nuclei, cells were stained with DAPI (5 μg/mL) at room temperature for 5 minutes, and then washed with PBS three times. For NF-κB (p65) staining, cells were incubated with the primary antibodies (NF-κB antibody, 1 : 500 dilution) for 2 hours at 37°C. Next, the cells were washed three times and incubated with secondary antibody (anti-rabbit Cy3, 1 : 500 dilution) for 1 hours at 37°C. Cells were covered with Prolong mounting medium and Prolong antifade reagent (Invitrogen, USA) and stored at 4°C. Cells were mounted and examined under a confocal laser scanning microscope (Leica, Germany).
2.10. Relative Quantification Detection of NF-κB (p65) Nuclear Translocation
NF-κB (p65) relative nuclear translocation quantitative detection kit (FIVEphoton Biochemicals, USA) has no radioactivity and high sensitivity and can detect specific-binding between DNA sites and transcription factors in nuclear extract protein. According to the manufacturer’s protocol, the specific double-stranded DNA (dsDNA) sequence containing the transcription factor NF-κB (p65) response element was preplaced inside the 96-well plates. NF-κB (p65) specific primary antibody (1 : 100 dilution) was added, followed by horseradish peroxidase-labeled secondary antibody (1 : 100 dilution). The absorbance was read at 450 nm on a microplate reader (TECAN, USA).
2.11. Statistical Analysis
Experiments were performed in triplicate. Each data point was presented as the mean ± standard deviation (SD). Comparisons between groups were analyzed using the -test. Statistical significance was evaluated using one-way ANOVA with SPSS 13.0 software. A value of was considered statistically significant.
3.1. ICA Has an Activation Effect on SIRT6 Enzyme Activity In Vitro
As shown in Figure 1, ICA shows a low percent activation effect (20% ± 4%) on the SIRT6 enzyme activity at the highest ICA concentration (10−4 mol/L). With decreasing concentrations of ICA, the activation effect on SIRT6 enzyme activity increased and reached a maximum (142% ± 10%) at a concentration of 10−8 mol/L. An activation effect of ICA on SIRT6 enzyme activity was detected even at very low concentrations of ICA (10−14, 10−16 mol/L).
3.2. Experiments on Animals
3.2.1. The Effect of ICA on SIRT6 Protein Expression in Heart Tissue
As shown in Figure 2, SIRT6 protein expression was detected in murine heart tissue isolated from the young, aged, and aged with ICA intervention groups. The results suggest that SIRT6 protein expression in aged mice hearts was decreased when compared with young mice. In the aged with ICA intervention group, SIRT6 protein expression was significantly upregulated in heart tissue compared with the aged group (Figure 2(b)).
3.2.2. The Effect of ICA on NF-κB (p65) Protein Expression in Heart Tissue
As shown in Figure 3, NF-κB (p65) protein expression was detected mouse heart tissue isolated from the young, aged, and aged with ICA intervention groups. The results suggest NF-κB (p65) protein expression was increased in aged mice hearts compared with young mice. In the aged with ICA intervention group, NF-κB (p65) protein expression was decreased in heart tissue compared with the aged mice.
3.3. The Result of Detection of SA-β-Gal in In Vitro Mouse Aortic ECs
Figure 4 shows that the percentage of SA-β-gal-positive cells in the TNF-α-treated young group was significantly higher () compared with the young group. After the cells in normal group were treated with TNF-α and ICA, the percentage of blue-stained cells was significantly decreased (). These data show that TNF-α can induce endothelial cell senescence in young cells and the effect can be suppressed by ICA treatment.
3.4. The Results of Aortic Endothelial Cells (ECs) Experiments
3.4.1. The Effect of ICA on SIRT6 and NF-κB (p65) Protein Expression in Each Group of Aortic ECs
Figure 5(a) shows that after induction of mild inflammation in aortic endothelial cells by addition of exogenous TNF-α, NF-κB (p65) protein expression was upregulated significantly, while Figure 5(b) shows there was no effect on SIRT6 protein expression. Addition of ICA to TNF-α treated cells significantly upregulated protein expression of SIRT6 (Figure 5(b)) while downregulating NF-κB (p65) (Figure 5(a)).
3.4.2. The Effect of ICA on mRNA Expression of SIRT6 and NF-κB (p65) Downstream Inflammatory Cytokines
As shown in Figure 6(a), treatment with the proinflammatory cytokine TNF-α increased mRNA levels of SIRT6 compared with young control cells treated with PBS or DMSO. With the intervention of ICA, PDTC, Nicotinamide alone, or all together, compared to TNF-α group, there was a significant increase in SIRT6 mRNA level. The increase was highest in the ICA treatment group. There were no significant differences between the TNF-α + ICA + PDTC, TNF-α + ICA + Nicotinamide, or TNF-α + ICA + PDTC + Nicotinamide treated groups compared with the TNF-α + ICA treated group ().
In Figure 6(b) after addition of TNF-α, mRNA levels of NF-κB (p65) downstream inflammatory cytokines (TNF-α, ICAM-1, IL-2, and IL-6) were increased compared with young control cells treated with PBS or DMSO. The increase in TNF-α mRNA levels was the highest. After the intervention with ICA, the increased mRNA levels of TNF-α, ICAM-1, IL-2, and IL-6 were all significantly decreased. The decrease in TNF-α mRNA levels was the greatest of the four cytokines tested (). When ICA and PDTC (NF-κB nuclear translocation blocker) were added together, this resulted in a further decrease in mRNA levels of TNF-α, ICAM-1, IL-2, and IL-6. Nicotinamide treatment partially reversed the effect of ICA, with significant increases in TNF-α and ICAM-1 mRNA levels. Treatment with ICA + PDTC + Nicotinamide significantly increased mRNA levels of the four inflammatory genes compared with the TNF-α + ICA + PDTC treated group and completely reversed the effect of ICA on ICAM-1 levels.
3.4.3. Qualitative Assessment of the Effect of ICA on NF-κB (p65) Nuclear Translocation
NF-κB (p65) is normally present in the cytoplasm in an inactive state. Figure 7(a) shows that very low NF-κB (p65) cytoplasmic protein was detected in young aortic ECs treated with PBS and DMSO. Following TNF-α treatment for 30 mins, NF-κB (p65) protein is detected in the cytoplasm and at qualitatively increased levels in nucleus (Figure 7(b)). After TNF-α treatment, and intervention of ICA for 12 hours, NF-κB (p65) protein decreases in the nucleus (Figure 7(c)) and qualitatively is further reduced upon addition of PDTC [specific inhibitor of NF-κB (p65)] (Figure 7(d)). The NF-κB (p65) signal in the nucleus is qualitatively increased when the Nicotinamide (SIRT6 inhibitor) is added in the presence of PDTC (Figure 7(e)).
3.4.4. The Effect of ICA on NF-κB (p65) Nuclear Translocation (Relative Quantification)
Figure 8 shows that NF-κB (p65) nuclear translocation relative in the young + DMSO group is 0.56 0.08. After the addition of TNF-α, the relative value increased significantly to 1.5 0.1 (). The relative values of the young + TNF-α + ICA (0.9 0.04) were significantly decreased compared with the young + TNF-α group (). Upon addition of PDTC (young + TNF-α + ICA + PDTC group) levels were decreased (0.68 0.06) relative to the young + TNF-α + ICA group (). Treatment with Nicotinamide reversed the effect of PDTC ().
A concentration range of ICA from 10−4 to 10−16 mol/L was used in an in vitro assay to detect an activation effect on the enzyme activity of SIRT6. ICA showed a low activation effect on the enzymatic activity of SIRT6 at high concentrations of ICA (10−4 mol/L) but, with decreasing concentrations of ICA, activation of SIRT6 enzyme activity occurred and reached the peak value at an ICA concentration of 10−8 mol/L. There was evidence for an activation effect of ICA on SIRT6 even at quite low drug concentrations of 10−16 mol/L. These data suggest that an ICA concentration of 10−8 mol/L gives an optimal activation effect on the enzymatic activity of SIRT6. We cannot rule out the possibility that at high ICA concentrations (10−4 mol/L) there is a substrate inhibition or a toxic effect on SIRT6 enzyme activity.
The natural aging process is associated with chronic, low-grade, mild inflammation. In 2000, Franceschi et al. found that the serum level of IL-6 is very low in young people but with aging to 60 years, the levels of IL-6 increased gradually. This phenomenon, called inflammaging (inflammation-aging) [22–24], and this condition are now thought to be critical in the onset of sarcopenia, frailty, and the pathogenesis of several age-related chronic diseases, such as Parkinson’s and Alzheimer’s disease (AD), atherosclerosis, and type 2 diabetes [25–29]. These diseases (and disabilities) appear to share the same process of inflammation, leading to the concept of an age-related “diseasome” . Accordingly, genes and epigenetic factors involved in the regulatory pattern of inflammation are expected to play a role in human ageing.
Through receptor-mediation, inflammatory cytokines including IL, interferons, TNF, colony stimulating factor, and TGF can participate in the complex cell-cell regulatory network in the body through paracrine and/or autocrine effects. In some cases these factors enter the circulation, causing systemic effects. By interacting with each other, many inflammatory cytokines constitute the inflammatory cytokine network , which can be divided into two types: the proinflammatory cytokine network (TNF-α, IFN-2γ, IL-1, IL-6, and IL-8) and the anti-inflammatory cytokine network (TGF-β1, IL-4, IL-10, and IL-13).
Important physiological functions regulate the growth and differentiation of immune cells and the body’s defense reaction. NF-κB is an important factor that regulates and controls gene expression of many cytokines, cell adhesion molecules, chemotactic factors, and the acute response proteins. Following activation, NF-κB can enhance the gene transcription levels of TNF-α, IL-1, IL-6, IL-8, ICAM-1, and other cytokines and thereby participate in the body’s immune defense response [32–34].
The immune response is crucial for the body’s normal physiological function. Inflammation can be of moderate benefit but is otherwise harmful. The change in the inflammatory cytokine network controls the direction of the development of inflammation. The dynamic counterbalance between the proinflammatory cytokine network and the anti-inflammatory cytokine network jointly maintain the balance between the proinflammatory and anti-inflammatory response systems, thereby safeguarding the normal physiological function of inflammation. The loss of physiological control of the inflammatory reaction is likely due to an imbalance of the finely tuned equilibrium between the levels of pro- and anti-inflammatory cytokines. When the balance is perturbed, this can lead to a chronic “proinflammatory” status, which promotes or exacerbates the above mentioned pathological conditions . The final result of the counterbalance between pro- and anti-inflammatory cytokines (IL-4, IL-6, IL-13, and IL-10) is an upregulation of the proinflammatory response .
Studies of the functional effect(s) and mechanism of SIRT6 focus on three aspects [13, 36, 37]. Firstly, the influence of SIRT6 on the repair of DNA damage. Secondly, the influence of SIRT6 on aging and inflammation, where the key target is NF-κB (p65). Thirdly, the influence of SIRT6 on the steady state that maintains the body’s energy metabolism and where the key target is hypoxia-inducible factor 1 (Hif-1α).
To date, there is no evidence that ICA can affect NF-κB (p65), a key regulator of inflammation, by affecting SIRT6, an important enzyme in aging regulation and control. In this study we provided experimental evidence for a direct, or indirect, interaction between ICA, SIRT6, and NF-κB. We showed that ICA can upregulate SIRT6 protein expression and downregulate NF-κB (p65) protein expression in animal tissues and cell models.
We provided evidence that, following treatment of aortic ECs with TNF-α, the mRNA expression level of SIRT6 was increased. Treatment with TNF-α and ICA however resulted in a significant increase in SIRT6 mRNA relative to TNF-α treatment alone. TNF-α and ICA treated cells subsequently treated with PDTC (NF-κB inhibitor), Nicotinamide (SIRT6 inhibitor), or PDTC and Nicotinamide showed a trend of decreasing SIRT6 mRNA levels but these decreases were not significant when compared with TNF-α and ICA treatment (Figure 6(a)). Although these data support that ICA upregulates SIRT6, the effects on SIRT6 and NF-κB, could be indirect.
We showed that treatment of young aortic ECs with the proinflammatory cytokine TNF-α resulted in increased levels of inflammatory cytokines that are downstream targets of NF-κB (TNF-α, ICAM-1, IL-2, and IL-6), with TNF-α mRNA levels showing the greatest increase (Figure 6(b)). ICA intervention resulted in significantly decreased mRNA levels of all four inflammatory cytokines. Addition of PDTC to inhibit NF-κB resulted in a further reduction in the expression of the four inflammatory cytokines but the reduction was not significant. These data suggest ICA can act as an inhibitor of NF-κB. Treatment with TNF-α, ICA and the SIRT6 inhibitor Nicotinamide partially reversed the effects of ICA with respect to TNF-α and ICAM-1 mRNA levels. These data suggest that ICA can act as an agonist of SIRT6. Treatment with ICA and PDTC and Nicotinamide increased the expression of all four proinflammatory cytokines when compared with ICA and PDTC treatment. Treatment with ICA and PDTC and Nicotinamide completely reversed the effects of ICA on ICAM-1 mRNA levels and substantially reduced the effects of ICA on TNF-α, IL-2, and IL-6 mRNA levels. These data suggest that ICA can act through either the NF-κB and SIRT6 pathways to regulate the expression of inflammatory cytokines. The synergistic effect suggests that ICA can affect the inflammation signal pathway of NF-κB through SIRT6.
We conclude that ICA had a stimulatory effect on SIRT6 enzyme activity in vitro, even at very low concentrations. ICA can upregulate SIRT6 protein expression and downregulate NF-κB (p65) protein expression in murine heart tissues and in an aortic EC model. ICA upregulated the expression of SIRT6 and had an inhibitory effect on NF-κB inflammatory signaling pathways by decreasing the mRNA levels of NF-κB downstream target genes TNF-α, ICAM-1, IL-2, and IL-6. Those effects were mediated directly or indirectly by SIRT6. We have provided tentative evidence that inflammaging may involve a link between the effects of ICA on SIRT6 (a regulator of aging) and NF-κB (a regulator of inflammation).
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Yang Chen, Tao Sun, and Junzhen Wu contributed equally to this work and should be considered the first authors.
This work was supported by the National Natural Science Foundation of China (Grant nos. 31171129 and 81273895) and the National Basic Research Program of China (no. 2010CB530402).
- L.-K. Pei, B.-L. Guo, S.-Q. Sun, and W.-H. Huang, “Study on the identification of some species of Herba Epimedii with FTIR,” Guang Pu Xue Yu Guang Pu Fen Xi, vol. 28, no. 1, pp. 55–60, 2008.
- S. C. Wing Sze, Y. Tong, T. B. Ng, C. L. Yin Cheng, and H. P. Cheung, “Herba Epimedii: anti-oxidative properties and its medical implications,” Molecules, vol. 15, no. 11, pp. 7861–7870, 2010.
- Z.-W. Hu, Z.-Y. Shen, and J.-H. Huang, “Experimental study on effect of epimedium flavonoids in protecting telomere length of senescence cells HU,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 24, no. 12, pp. 1094–1097, 2004.
- W.-J. Cai, X.-M. Zhang, and J.-H. Huang, “Effect of Epimedium flavonoids in retarding aging of C. elegans,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 6, pp. 522–525, 2008.
- Z. Y. Shen, C. Y. Yuan, J. H. Huang, et al., “The efficacy of epimedium flavonoids on senescence-delaying in Drosophila and its under-lying molecular mechanisms,” Chinese Journal of Gerontology, vol. 9, pp. 1061–1063, 2005.
- B. Wu, S. Yan, Z. Lin, et al., “Metabonomic study on ageing: NMR-based investigation into rat urinary metabolites and the effect of the total flavone of Epimedium,” Molecular BioSystems, vol. 4, no. 8, pp. 855–861, 2008.
- S. Yan, B. Wu, Z. Lin et al., “Metabonomic characterization of aging and investigation on the anti-aging effects of total flavones of Epimedium,” Molecular BioSystems, vol. 5, no. 10, pp. 1204–1213, 2009.
- W.-J. Cai, J.-H. Huang, S.-Q. Zhang et al., “Icariin and its derivative icariside II extend healthspan via insulin/IGF-1 pathway in C. elegans,” PLoS ONE, vol. 6, no. 12, Article ID e28835, 2011.
- R. M. de Oliveira, T. F. Pais, and T. F. Outeiro, “Sirtuins: common targets in aging and in neurodegeneration,” Current Drug Targets, vol. 11, no. 10, pp. 1270–1280, 2010.
- R. A. Frye, “Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (Sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity,” Biochemical and Biophysical Research Communications, vol. 260, no. 1, pp. 273–279, 1999.
- R. A. Frye, “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins,” Biochemical and Biophysical Research Communications, vol. 273, no. 2, pp. 793–798, 2000.
- R. I. Tennen and K. F. Chua, “Chromatin regulation and genome maintenance by mammalian SIRT6,” Trends in Biochemical Sciences, vol. 36, no. 1, pp. 39–46, 2011.
- A. Kaidi, B. T. Weinert, C. Choudhary, and S. P. Jackson, “Human SIRT6 promotes DNA end resection through CtIP deacetylation,” Science, vol. 329, no. 5997, pp. 1348–1353, 2010.
- R. Mostoslavsky, K. F. Chua, D. B. Lombard et al., “Genomic instability and aging-like phenotype in the absence of mammalian SIRT6,” Cell, vol. 124, no. 2, pp. 315–329, 2006.
- C. Xiao, H.-S. Kim, T. Lahusen et al., “SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice,” The Journal of Biological Chemistry, vol. 285, no. 47, pp. 36776–36784, 2010.
- H.-S. Kim, C. Xiao, R.-H. Wang et al., “Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis,” Cell Metabolism, vol. 12, no. 3, pp. 224–236, 2010.
- G. Natoli, “When Sirtuins and NF-κB Collide,” Cell, vol. 136, no. 1, pp. 19–21, 2009.
- A. Salminen, J. Ojala, J. Huuskonen, A. Kauppinen, T. Suuronen, and K. Kaarniranta, “Interaction of aging-associated signaling cascades: Inhibition of NF-κB signaling by longevity factors FoxOs and SIRT1,” Cellular and Molecular Life Sciences, vol. 65, no. 7-8, pp. 1049–1058, 2008.
- T. L. A. Kawahara, E. Michishita, A. S. Adler et al., “SIRT6 links histone H3 lysine 9 deacetylation to NF-κB-dependent gene expression and organismal life span,” Cell, vol. 136, no. 1, pp. 62–74, 2009.
- N. Kipshidze, J. J. Ferguson III, M. H. Keelan Jr. et al., “Endoluminal reconstruction of the arterial wall with endothelial cell/glue matrix reduces restenosis in an atherosclerotic rabbit,” Journal of the American College of Cardiology, vol. 36, no. 4, pp. 1396–1403, 2000.
- Y. Ding and N. D. Vaziri, “Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells,” Hypertension, vol. 32, no. 4, pp. 718–723, 1998.
- C. Franceschi, M. Bonafè, S. Valensin et al., “Inflamm-aging. An evolutionary perspective on immunosenescence,” Annals of the New York Academy of Sciences, vol. 908, pp. 244–254, 2000.
- C. Franceschi, M. Capri, D. Monti et al., “Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans,” Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 92–105, 2007.
- C. Franceschi, “Inflammaging as a major characteristic of old people: can it be prevented or cured?” Nutrition Reviews, vol. 65, no. 3, pp. S173–S176, 2007.
- S. Vasto, G. Candore, C. R. Balistreri et al., “Inflammatory networks in ageing, age-related diseases and longevity,” Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 83–91, 2007.
- M. de Martinis, C. Franceschi, D. Monti, and L. Ginaldi, “Inflammation markers predicting frailty and mortality in the elderly,” Experimental and Molecular Pathology, vol. 80, no. 3, pp. 219–227, 2006.
- M. de Martinis, C. Franceschi, D. Monti, and L. Ginaldi, “Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity,” FEBS Letters, vol. 579, no. 10, pp. 2035–2039, 2005.
- L. Ginaldi, M. De Martinis, D. Monti, and C. Franceschi, “Chronic antigenic load and apoptosis in immunosenescence,” Trends in Immunology, vol. 26, no. 2, pp. 79–84, 2005.
- S. Vasto, G. Carruba, D. Lio et al., “Inflammation, ageing and cancer,” Mechanisms of Ageing and Development, vol. 130, no. 1-2, pp. 40–45, 2009.
- M. Sander, K. Avlund, M. Lauritzen et al., “Aging-From molecules to populations,” Mechanisms of Ageing and Development, vol. 129, no. 10, pp. 614–623, 2008.
- S. Salvioli, M. Capri, S. Valensin et al., “Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology,” Current Pharmaceutical Design, vol. 12, no. 24, pp. 3161–3171, 2006.
- C. Potter, H. J. Cordell, A. Barton et al., “Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1315–1320, 2010.
- E. Abraham, “NF-kappaB activation,” Critical Care Medicine, vol. 28, no. 4, pp. 100–104, 2000.
- D. Kesanakurti, C. Chetty, D. Rajasekhar Maddirela, M. Gujrati, and J. S. Rao, “Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma,” Oncogene, vol. 10, pp. 1038–1043, 2012.
- D. Lio, L. Scola, A. Crivello et al., “Inflammation, genetics, and longevity: Further studies on the protective effects in men of IL-10-1082 promoter SNP and its interaction with TNF-α-308 promoter SNP,” Journal of Medical Genetics, vol. 40, no. 4, pp. 296–299, 2003.
- E. Michishita, R. A. McCord, E. Berber et al., “SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin,” Nature, vol. 452, no. 7186, pp. 492–496, 2008.
- D. B. Lombard, B. Schwer, F. W. Alt, and R. Mostoslavsky, “SIRT6 in DNA repair, metabolism and ageing,” Journal of Internal Medicine, vol. 263, no. 2, pp. 128–141, 2008.